{
    "root": "69c5248b-075b-40a6-a91d-3098cf9fa7c4",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": {
        "text": "Divalproex sodium"
    },
    "value": "20250317",
    "ingredients": [
        {
            "name": "DIVALPROEX SODIUM",
            "code": "644VL95AO6"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "GELATIN",
            "code": "2G86QN327L"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "D&C RED NO. 28",
            "code": "767IP0Y5NH"
        },
        {
            "name": "SHELLAC",
            "code": "MB5IUD6JUA"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T"
        },
        {
            "name": "ETHYLCELLULOSE (7 MPA.S)",
            "code": "H3UP11403C"
        }
    ],
    "indications": "divalproex sodium delayed-release capsules anti-epileptic indicated : \u2022 monotherapy adjunctive therapy complex partial seizures simple complex absence seizures ; adjunctive therapy patients multiple seizure types include absence seizures ( 1 )",
    "contraindications": "\u2022 divalproex sodium delayed-release capsules may swallowed whole contents may sprinkled soft food . drug/food mixture swallowed immediately ( avoid chewing ) ( 2.2 ) \u2022 safety doses 60 mg/kg/day established ( 2.1 , 2.2 ) \u2022 complex partial seizures : start 10 15 mg/kg/day , increasing 1 week intervals 5 10 mg/kg/day achieve optimal response ; response satisfactory , check valproate plasma level ; full prescribing information conversion monotherapy ( 2.1 ) \u2022 absence seizures : start 15 mg/kg/day , increasing 1 week intervals 5 10 mg/kg/day seizure control limiting side effects ( 2.1 )",
    "warningsAndPrecautions": "divalproex sodium delayed-release capsules , usp , oral 125 mg , transparent blue cap/opaque white body hard gelatin capsule size \u201c 1 \u201d imprinting \u201c \u2191 end \u2191 \u201d cap black ink \u201c d9 \u201d body black ink filled white white pellets . bottle 100 capsules child-resistant closure , ndc 62332-821-31 bottle 500 capsules , ndc 62332-821-71 bottle 1000 capsules , ndc 62332-821-91 unit dose package 100 capsules , ndc 62332-821-10 recommended storage : store 25\u00b0c ( 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) [ usp controlled room temperature ] .",
    "adverseReactions": "\u2022 divalproex sodium delayed-release capsules administered patients hepatic disease significant hepatic dysfunction [ ( 5.1 ) ] . \u2022 divalproex sodium delayed-release capsules contraindicated patients known mitochondrial disorders caused mutations mitochondrial dna polymerase \u03b3 ( polg ; e.g . , alpers- huttenlocher syndrome ) children two years age suspected polg-related disorder [ ( 5.1 ) ] . \u2022 divalproex sodium delayed-release capsules contraindicated patients known hypersensitivity [ ( 5.12 ) ] . \u2022 divalproex sodium delayed-release capsules contraindicated patients known urea cycle disorders [ ( 5.6 ) ] . \u2022 prophylaxis migraine headaches : divalproex sodium delayed-release capsules contraindicated women pregnant women childbearing potential using effective contraception [ ( 5.2 , 5.3 , 5.4 ) ( 8.1 ) ] .",
    "indications_original": "Divalproex sodium delayed-release capsules are an anti-epileptic drug indicated for: \u2022\u00a0 Monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures ( 1 )",
    "contraindications_original": "\u2022 Divalproex sodium delayed-release capsules may be swallowed whole or the contents may be sprinkled on soft food. The drug/food mixture should be swallowed immediately (avoid chewing) ( 2.2 ) \u2022 Safety of doses above 60 mg/kg/day is not established ( 2.1 , 2.2 ) \u2022 Complex Partial Seizures: Start at 10 to 15 mg/kg/day, increasing at 1 week intervals by 5 to 10 mg/kg/day to achieve optimal clinical response; if response is not satisfactory, check valproate plasma level; see full prescribing information for conversion to monotherapy ( 2.1 ) \u2022 Absence Seizures: Start at 15 mg/kg/day, increasing at 1 week intervals by 5 to 10 mg/kg/day until seizure control or limiting side effects ( 2.1 )",
    "warningsAndPrecautions_original": "Divalproex sodium delayed-release capsules, USP, for oral use 125 mg, are transparent blue cap/opaque white body hard gelatin capsule size \u201c1\u201d having imprinting \u201c\u2191 THIS END UP \u2191\u201d on cap with black ink and \u201cD9\u201d on body with black ink filled with white to off white pellets.\n                  \n                  Bottle of 100 capsules with child-resistant closure, NDC 62332-821-31\n                  Bottle of 500 capsules, NDC 62332-821-71 Bottle of 1000 capsules, NDC 62332-821-91 Unit Dose Package of 100 capsules, NDC 62332-821-10\n                  \n                  Recommended Storage: Store at 25\u00b0C (77\u00b0F); excursions permitted to 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "\u2022\u00a0 Divalproex sodium delayed-release capsules should not be administered to patients with hepatic disease or significant hepatic dysfunction [see Warnings and Precautions (5.1)]. \u2022\u00a0 Divalproex sodium delayed-release capsules are contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase \u03b3 (POLG; e.g., Alpers- Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder [see Warnings and Precautions (5.1)].\n                      \u2022\u00a0 Divalproex sodium delayed-release capsules are contraindicated in patients with known hypersensitivity to the drug [see Warnings and Precautions (5.12)].\n                      \u2022\u00a0 Divalproex sodium delayed-release capsules are contraindicated in patients with known urea cycle disorders [see Warnings and Precautions (5.6)].\n                      \u2022\u00a0 For use in prophylaxis of migraine headaches: Divalproex sodium delayed-release capsules are contraindicated in women who are pregnant and in women of childbearing potential who are not using effective contraception [see Warnings and Precautions (5.2, 5.3, 5.4) and Use in Specific Populations (8.1)]."
}